In the wake of the increase in Current Liabilities in the fourth quarter 2024, Quick Ratio fell to 0.05 below Kiromic Biopharma Inc average.

Within Biotechnology & Pharmaceuticals industry 150 other companies have achieved higher Quick Ratio than Kiromic Biopharma Inc in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 3146 to 4036.

Explain Quick Ratio?
How much Cash & cash equivalents KRBP�s has?
What are KRBP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

KRBP Quick Ratio	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4
Y / Y Current Liabilities Change	227.74 %	8.39 %	-8.79 %	-3.86 %	-53.81 %
Y / Y Cash & cash equivalent Change	-64.51 %	-33.23 %	49.69 %	78.94 %	396.59 %
Quick Ratio MRQ	0.05	0.15	0.24	0.19	0.5
KRBP's Total Ranking	# 4036	# 3146	# 2769	# 2409	# 2008
Seq. Current Liabilities Change	9.28 %	12.15 %	-10.66 %	199.34 %	-63.86 %
Seq. Cash & cash equivalent Change	-61.11 %	-27.77 %	10.12 %	14.73 %	-26.84 %

Quick Ratio fourth quarter 2024 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 151
Healthcare Sector	# 920
Overall Market	# 4036

Quick Ratio Statistics
High	Average	Low
37.9	3.8	0.04
(Sep 30 2021)		(Sep 30 2022)

Financial Statements
Kiromic Biopharma Inc 's Current Liabilities	$ 21 Millions	Visit KRBP's Balance sheet
Kiromic Biopharma Inc 's Cash & cash equivalent	$ 1 Millions	Visit KRBP's Balance sheet
Source of KRBP's Sales		Visit KRBP's Sales by Geography

Cumulative Kiromic Biopharma Inc 's Quick Ratio

KRBP's Quick Ratio for the trailling 12 Months

KRBP Quick Ratio	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	21.73 %	-11.94 %	-5.2 %	21.82 %	78.85 %
Y / Y Cash & cash equivalent TTM Growth	-4.51 %	41.59 %	162.28 %	44.81 %	-45.66 %
Quick Ratio TTM	0.15	0.22	0.25	0.23	0.2
Total Ranking TTM	# 3771	# 2245	# 3469	# 3591	# 2125
Seq. Current Liabilities TTM Growth	23.56 %	2.46 %	-2.66 %	-1.23 %	-10.61 %
Seq. Cash & cash equivalent TTM Growth	-14.92 %	-9.51 %	9.62 %	13.14 %	26.16 %

Quick ratio ranking by company, industry and sector >> Back to KRBP Financial Strength Comparisons >> Go to Compare KRBP Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q4 2024 to $20.90 millions, cumulative Quick Ratio decreased to 0.15 below the Kiromic Biopharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 151 other companies have achieved higher Quick Ratio than Kiromic Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 2245 to 3771.

Explain Quick Ratio?
How much Cash & cash equivalents KRBP�s has?
What are KRBP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 152
Healthcare Sector	# 955
Within the Market	# 3771

trailing twelve months Quick Ratio Statistics
High	Average	Low
9.02	2.41	0.09
(Sep 30 2021)		(Jun 30 2023)

Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2024 MRQ Cash & cash equivalent	Dec 31 2024 MRQ Current Liabilities
Tevogen Bio Holdings Inc	0.15	$ 1.283 Millions	$ 8.814 Millions
Aptose Biosciences Inc	0.12	$ 0.557 Millions	$ 4.459 Millions
Kiromic Biopharma Inc	0.05	$ 1.137 Millions	$ 20.904 Millions
Redwoods Acquisition Corp	0.05	$ 0.064 Millions	$ 1.248 Millions
Brainstorm Cell Therapeutics inc	0.02	$ 0.187 Millions	$ 8.978 Millions
Mosaic Immunoengineering Inc	0.02	$ 0.115 Millions	$ 5.537 Millions

Date modified: 2026-09-08T15:11:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.